The 12th Clinical Trials on Alzheimer’s Disease (CTAD) brings together worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Evidera will be presenting an oral communication at CTAD titled, Conducting Clinical Trial Simulation to Study Heterogeneity of Trial Outcomes in Amyloid-Modifying Drugs. Presenters include: Tafazzoli A, Chavan A, Kansal A.

Conference Website